A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects
Phase of Trial: Phase IV
Latest Information Update: 10 Apr 2016
Price : $35 *
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors VIVUS
- 31 Aug 2018 Biomarkers information updated
- 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.